Condition 1: Type 2 diabetes. Condition 2: overweight and obesity. Diabetes mellitus due to underlying condition Overweight and obesity
Conditions
Interventions
Intervention 1: Intervention group: Legume based dietary approach to stop hypertension diet with weight reduction. Intervention 2: Control group: Dietary approach to stop hypertension diet with weight
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Agreement to participate in the study and completing informed consent form Fasting blood glucose =126 mg/dl or 2-h plasma glucose =200 mg/dl or treatment with anti-hyperglycemic medications Aged 35-65 years old Body mass index between 25-40 kg/m2 No weight change in past three months determining transcription factor-7-like 2 rs7903146 genotypes
Exclusion criteria
Exclusion criteria: Cardiovascular disease such as myocardial infarction in past 6 months Renal disease (creatinine 1.4 = mg/dl for men or =1.3 mg/dl for women) Alcohol intake, either acute or chronic Using anti inflammatory drugs Following any specific diet in past three months Gastrointestinal disease (e.g. inflammatory bowel diseases) lower desire or lack of desire to consume legumes Insulin treatment Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzymatic method.;High sensitive C reactive protein. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma concentration of total cholesterol. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzymatic method.;Plasma concentration of low density lipoprotein cholesterol. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzymatic method.;Plasma concentration of high density lipoprotein cholesterol. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzymatic method.;Plasma triglyceride concentration. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzymatic method.;Tumor necrosis factor alpha concentration. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzyme-linked immunosorbent assay.;Interleukin 6. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzyme-linked immunosorbent assay.;Fibrinogen concentration. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Turbiditymeter.;Plasma catalase activity. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Catalase activity assay kit.;Plasma insulin concentration. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Enzyme-linked immunosorbent assay.;Total antioxidant capacity. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Colorimetric.;Malondialdehyde concentration. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Colorimetric.;Systolic blood pressure. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Mercury sphygmomanometers.;Diastolic blood pressure. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Mercury sphygmomanometers.;Weight. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Scales. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSomayeh Hosseinpour
Shahid Beheshti University of Medical Sciences
Outcome results
None listed